at Zacks.com (Jan 22, 2015)
Arena Pharmaceuticals (ARNA) slides 7.8% and adds to a 6.5% loss on Friday after the EU's CHMP health regulator didn't make a decision about approving the company's Belviq weight-loss treatment at meetings last week, meaning the firm will have to wait for at least another month for a ruling. It doesn't help that Arena received a 180-day list of questions about Belviq. "It's not pretty," says Adam Feuerstein. (Arena 8-K)
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Jan 16, 2015)
at Zacks.com (Jan 15, 2015)
at Benzinga.com (Jan 14, 2015)
at Benzinga.com (Jan 13, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs